Global Psoriasis Drugs Market Size

Statistics for the 2023 & 2024 Global Psoriasis Drugs market size, created by Mordor Intelligence™ Industry Reports. Global Psoriasis Drugs size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Global Psoriasis Drugs Industry

Single User License
Team License
Corporate License
Book before:
Psoriasis Drugs Market Size
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 9.89 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Psoriasis Drugs Market Analysis

The psoriasis drugs market is expected to register a CAGR of 9.89% during the forecast period, 2022-2027.

The COVID-19 pandemic initially had an adverse impact on the psoriasis market, mainly because of the guidelines published by various regulatory bodies suggesting that patients receiving psoriasis treatment are at more risk of getting infected by COVID-19. In March 2020, the International Psoriasis Council (IPC) recommended physicians to discontinue or postpone the prescription of immunosuppressant medications. However, later in September 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania and 16 other research institutions from the United States and Canada, in collaboration with the National Psoriasis Foundation, created guidelines to care for patients with psoriasis during the coronavirus pandemic. The scientists found no evidence that medical interventions to treat psoriasis and psoriatic arthritis should be interrupted or altered to minimize COVID-19 risks. Such guidelines are expected to augment the market growth pace over the pandemic phase.

An increasing disease burden and demand for psoriasis medicines in emerging economies and the increase in psoriasis research and pipeline drugs are the major factors responsible for the market's growth. Novel drugs with oral administration are opening avenues for needle-averse patients. For instance, in November 2020, Bristol Myers Squibb presented Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in patients with psoriatic arthritis. It is a driving factor for better uptake among patients averse to injectables.

Also, in December 2021, Amgen received the United States Food and Drug Administration approval for Otezla (apremilast) for treating adult patients with plaque psoriasis. In addition, key players in the market are involved in various business strategies, such as product launches, to expand their product portfolios and gain a competitive edge in the market.

Due to the abovementioned factors, the market is expected to register a high growth rate during the forecast period. However, the adverse side effects of most of the existing medications and the high cost of treatment are expected to hamper the market's growth.

Psoriasis Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)